Sensus Healthcare, Inc. (SRTS) Fair Value 2026

SRTS · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.3 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, Sensus Healthcare, Inc. (SRTS) trades at $3.52, versus a $1.55 median fair value across its 5 active models — 55.9% below the current price. QOC: 7.3/10. Value Trap Risk: 39/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $0.93.

Key Facts

Ticker
SRTS
Price
$3.52
Quality Score
7.3/10
Value Trap Risk
39/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Sensus Healthcare, Inc. (SRTS) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Sensus Healthcare, Inc. (SRTS) appears overvalued as of : the median of 5 independent fair value estimates is $1.55, 55.9% below the current price of $3.52. Estimates range from $0.92 to $4.15. SRTS scores 7.3/10 on fundamental quality and 39/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. SRTS’s -55.9% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Sensus Healthcare, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SRTS?

5 Intrinsic Value Models vs. Current Price ($3.52)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.93 -73.7%
Ensemble · Low Conviction
 $1.55 -55.9%
Unlock the Full Matrix

Access 3 additional models including Dynamic NAV, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is SRTS's Fair Value Range?

Spread across 5 independent models · $0.92 to $4.15

CirclFi's 5 active models place Sensus Healthcare, Inc. (SRTS) between $0.92 and $4.15 per share, a spread of 208% of the median. The median of that range — $1.55 — is the fair value CirclFi publishes for SRTS, against a current price of $3.52.

Low · RCMH-DCFHigh · FTNN
$0.92median $1.55$4.15
Where the range comes from
Most bearish modelRCMH-DCF$0.92
Most bullish modelFTNN Topology$4.15
Model agreement1 bullish · 4 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for SRTS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on SRTS, not a CirclFi price target. How each model works →

What Is Sensus Healthcare, Inc. (SRTS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sensus Healthcare, Inc.'s intrinsic value is estimated at $1.55. Trading at its current price of $3.52, the valuation engine raises significant caution: 4 of 5 models flag downside risk, projecting a median implied return of -55.9%. Model dispersion is worth noting: FTNN targets $4.15 (+17.9%), versus RCMH-DCF at $0.92 (-73.8%). This +91.7% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SRTS?

5 of 13 models are currently active for SRTS. Of these, 1 model suggests upside while 4 models suggest overvaluation. Taken together, their median fair value for SRTS is $1.55 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.93 on its own, implying -73.7% downside from the current price. See which stocks rank higher →

How Does SRTS Rank in Medical Devices?

Among 159 Medical Devices stocks, SRTS ranks #39 by Quality of Company score. CirclFi's QOC score of 7.3/10 evaluates 32 fundamental signals. A score of 7.3 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Sensus Healthcare, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is SRTS a Value Trap?

CirclFi's Value Trap algorithm assigns SRTS a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Sensus Healthcare, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Sensus Healthcare, Inc. scores 7.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +91.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SRTS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SRTS's 5 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sensus Healthcare, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

VREXVarex Imaging CorporationQOC 7.3SGHTSight Sciences, Inc.QOC 7.3SNWVSANUWAVE Health, Inc.QOC 7.4AORTArtivion, Inc.QOC 7.3DCTHDelcath Systems, Inc.QOC 7.4LUNGPulmonx CorporationQOC 7.2PETVPetVivo Holdings, Inc.QOC 6.3IRIXIRIDEX CorporationQOC 5.2BWAYBrainsWay Ltd.QOC 2.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: VREX · SGHT · SNWV · AORT · DCTH · LUNG · PETV · IRIX · BWAY · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to SRTS?

7 companies across all industries closest to SRTS’s Quality of Company score of 7.3/10.

ADNTAdient plcQOC 7.3STNGScorpio Tankers Inc.QOC 7.3EEni S.p.A.QOC 7.3FMCCFederal Home Loan Mortgage CorporationQOC 7.3RGCORGC Resources, Inc.QOC 7.3NCINeo-Concept International Group Holdings LimitedQOC 7.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ADNT · STNG · E · FMCC · RGCO · NCI · NVDA

Where Does SRTS Sit in CirclFi's Medical Devices Rankings?

SRTS is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Sensus Healthcare, Inc.’s Valuation?

What is Sensus Healthcare, Inc.'s intrinsic value in 2026?

CirclFi puts Sensus Healthcare, Inc. (SRTS)'s intrinsic value at $1.55 — the median of 5 independent model estimates as of 2026-08-28, ranging from $0.92 to $4.15. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.93 on its own. The Quality of Company score is 7.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SRTS overvalued or undervalued right now?

At $3.52, 1 of 5 active models suggest SRTS may be undervalued, while 4 indicate potential overvaluation. The median of all 5 fair value estimates is $1.55, 55.9% below the current price of $3.52 — a consensus view that SRTS is overvalued. The assessment depends on which methodology best fits Sensus Healthcare, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 7.3 mean for SRTS?

Sensus Healthcare, Inc.'s QOC of 7.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SRTS?

CirclFi analyzes SRTS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SRTS?

Of the 5 models currently active on SRTS, FTNN Topology is the most bullish at $4.15 per share, and RCMH-DCF is the most bearish at $0.92. CirclFi's published fair value for SRTS is the median of that range, $1.55, not either extreme. The gap between the two ends equals 208% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is SRTS a value trap in 2026?

Sensus Healthcare, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Sensus Healthcare, Inc. (SRTS) has a median fair value of $1.55 — 55.9% below the current price of $3.52 — as of 2026-08-28.” Source: circlfi.com/stock/SRTS/ · Methodology
Primary sources for this SRTS valuation
  • Financial statements: Sensus Healthcare, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001494891) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SRTS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on SRTS.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for SRTS Unlock All 5 — $39/mo